Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

Autor: Alejandro Hernández-Camba, Federico Bertoletti, Luis Ferrer Arranz, Geteccu, Marisa Iborra, E Sánchez Rodríguez, David Busquets, Alfredo J. Lucendo, Carlos Taxonera, C Tardillo, I Rodríguez-Lago, Olga Merino, S. Marín, J M Huguet Malavés, M. Sierra Ausín, Ana Yaiza Carbajo, Luis Bujanda, M. García, E. Domènech, A Martín-Cardona, G. Suris Marin, M Calafat, A Castaño, Daniel Carpio, L Ramos, M.L. De Castro, Isabel Vera
Rok vydání: 2022
Předmět:
Zdroj: DIGESTIVE AND LIVER DISEASE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
ISSN: 1590-8658
Popis: Background Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments. Aims Our primary objective was to evaluate the effectiveness and safety of MMF in IBD. Methods IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey‐Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented. Results A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR: 20.4–37.5). Conclusion Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD.
Databáze: OpenAIRE
Externí odkaz: